Eli Lilly, a leader in the pharmaceutical industry, has announced its agreement to pay up to $7.8 billion to acquire Centessa Pharmaceuticals, which is working on developing experimental drugs to treat sleep disorders such as narcolepsy, a condition that causes difficulty in staying awake during the day. This announcement was made on Tuesday and reflects Eli Lilly's commitment to expanding its research in the neurology field.
Centessa is one of several companies developing a new class of drugs to treat narcolepsy, which affects millions of people worldwide. The drugs being developed by Centessa may also be used to treat other neurological conditions associated with drowsiness, such as Alzheimer's disease and depression, opening new avenues for addressing these conditions.
Details of the Acquisition
Under the terms of the deal, Eli Lilly will pay $38 per share, which means the acquisition value reaches $6.3 billion, representing a 38% increase compared to the stock's closing price on Monday. If Centessa's drugs receive approval from the U.S. Food and Drug Administration (FDA) by specified deadlines, Eli Lilly will pay up to an additional $1.5 billion.
The deal is expected to close in the third quarter of the year, pending necessary regulatory approvals. Eli Lilly's shares rose by 3% on Tuesday, while Centessa's shares jumped by 45%.
Background & Context
Eli Lilly is considered a leader in the psychiatric drug market, having contributed to the development of many drugs that have changed patients' lives. The drug Prozac, approved in 1987, was a turning point for the company, positioning it at the forefront of the pharmaceutical industry. Recently, the company introduced a new drug called Qysmia to treat early stages of Alzheimer's disease, reflecting its ongoing interest in innovation in the neurology field.
Centessa is developing drugs targeting orexin receptors, which represent a significant opportunity in neurology as a means to directly intervene in the sleep-wake cycle. Dr. Carol Ho, head of the neurology department at Eli Lilly, noted that Centessa has a broad portfolio of drugs that could enhance alertness across a variety of indications.
Impact & Consequences
Estimates suggest that the market for drugs treating narcolepsy and idiopathic hypersomnia could reach $15 to $20 billion if a quarter of patients seek treatment. Sales are expected to rise if the drugs are used more widely. However, Centessa will not be the first in the market, as there is a competing drug from Takeda under review by the FDA.
Analysts expect that Centessa's drug will not receive approval before 2028, but there are indications from mid-stage clinical trial data that Centessa's treatment may become the best in its class.
Regional Significance
This deal is significant in the context of drug development in the Arab region, where many countries suffer from high rates of sleep disorders. The introduction of new drugs to the market could improve the quality of life for many patients in the Arab world, reflecting the importance of innovation in public health.
In conclusion, this acquisition reflects the growing trend towards developing new drugs for sleep disorders, opening new horizons in medical research and enhancing companies' ability to meet patients' needs.